Skip to main content

Vaccine Formulation Guidance

Developing new vaccines represents a lengthy, intense and resource challenge, incentivizing multiple actors to collaborate from the design to the approval of the vaccine.

Antigen Compatibility.

Saponin adjuvants have been incorporated in multiple vaccine platforms and have been shown to be compatible with all types of antigens, either as standalone or formulated adjuvant. Q-VANT can also test the compatibility of particular saponin adjuvants with specific antigens.

Antigen type
Formulation requirement
Virus
TBD
Bacteria
TBD
Spores
TBD
Toxoid
TBD
Protein and subunit
TBD
DNA
TBD
mRNA
Yes
Saccharide
TBD
Yeast based
TBD
Glycoconjugate
None
VLP
Yes

Compatibility with Other Adjuvants.

Synergies between adjuvants and other substances have shown promising results in enhancing the immune response or improving the safety of a vaccine.

Combinations or adjuvant systems with saponins and other adjuvant technologies have been thoroughly studied and exist in several commercial veterinary and approved vaccines for humans. Q-VANT offers developers support in the assessment and the compatibility of particular saponin adjuvants with other adjuvants adjuvant technologies.

Adjuvant technology
Compatibility
Liposome-based adjuvants
Yes
Particulates
Yes
Mineral salts
Yes
Emulsions
Yes
Nucleic acid /Nucleotides
Yes
Toxins
Yes
Carbohydrate /Polysaccharide
Yes
Peptides /Lipopeptides /Peptidoglycans
Yes
Proteins
Yes
Lipids
Yes
Cytokines and chemokines
Yes

Use and formulation guide

Q-VANT’s book will help you to delve into the uses and formulations of saponin adjuvants.

Request information